Related Experiment Video
Updated: Jun 12, 2025

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Causal Relationships of Circulating Inflammatory Proteins and Portal Vein Thrombosis: A Mendelian Randomization Study
Bihui Zhang1, Ziping Yao1, Pengyu Li1
1Department of Interventional Radiology and Vascular Surgery, Peking University First Hospital, Beijing, China.
Abstract:
Portal vein thrombosis (PVT) is commonly encountered in patients with cirrhosis, challenging our understanding of its development, particularly the ambiguous contribution of inflammation. This study utilized Mendelian randomization (MR) to explore the causal impact of circulating inflammatory markers on PVT.Employing a two-sample MR framework, we merged genome-wide association study (GWAS) meta-analysis findings of 91 inflammation-associated proteins with independent PVT data from the FinnGen consortium's R10 release. A replication analysis was performed using a distinct GWAS dataset from the UK Biobank. Inverse variance weighting, MR-Egger regression, weighted median estimator, and Mendelian Randomization Pleiotropy RESidual Sum and Outlier were used for analysis, supplemented by multivariable MR (MVMR) to adjust for cirrhosis effects.Findings indicate a significant inverse association between the genetically inferred concentration of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and PVT risk, evidenced by an odds ratio (OR) of 0.37 (95% confidence interval [CI]: 0.21-0.67; p = 9.2 × 10-4; adjusted for multiple testing p = 0.084). This association was corroborated in the replication phase (OR = 0.39, 95% CI: 0.17-0.93; p = 0.03) and through MVMR analysis (OR = 0.34, 95% CI: 0.15-0.79; p = 0.012). Sensitivity analyses disclosed no evidence of heterogeneity or pleiotropy.Our investigation emphasizes the 4E-BP1 as a protective factor against PVT, underscoring its potential relevance in understanding PVT pathogenesis and its implications for diagnosis and therapy.
Insights
This study found that higher levels of eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) are associated with a reduced risk of portal vein thrombosis (PVT). This suggests 4E-BP1 may play a protective role in PVT development.
Area of Science:
- Genetics
- Gastroenterology
- Immunology
Background:
- Portal vein thrombosis (PVT) is a significant complication in cirrhosis patients.
- The role of inflammation in PVT development remains unclear.
- Understanding PVT pathogenesis is crucial for improved patient outcomes.
Purpose of the Study:
- To investigate the causal relationship between inflammatory markers and PVT.
- To identify potential therapeutic targets for PVT.
Main Methods:
- Utilized a two-sample Mendelian randomization (MR) approach.
- Integrated genome-wide association study (GWAS) data for 91 inflammation proteins with PVT data from FinnGen and UK Biobank.
- Employed various MR analyses, including multivariable MR (MVMR) to adjust for cirrhosis.
Main Results:
- A significant inverse causal association was found between genetically inferred eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) levels and PVT risk (OR=0.37).
- This finding was robustly replicated in an independent cohort and confirmed via MVMR analysis.
- Sensitivity analyses ruled out heterogeneity and pleiotropy, supporting the causal inference.
Conclusions:
- Eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) acts as a protective factor against portal vein thrombosis.
- 4E-BP1 warrants further investigation for its role in PVT pathogenesis and potential as a therapeutic target.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
The JAK-STAT Signaling Pathway
Intracellular Signaling Affects Focal Adhesions
Some...
Inflammation

